葉茂，男，病理學與病理生理學博士，湖南大學教授，湖南大學生物學院院長助理（分管生物醫學研究與測試平臺工作）。2006年入選溫州市“新世紀551人才工程”第二層次培養人選。2007年入選浙江省高校中青年學科帶頭人培養對象。
人物經歷
學習經歷
1991年09月至1995年07月，畢業于湖南師范大學生物教育專業，獲學士；
1996年09月至1999年07月，畢業于湖南農業大學植物病理學專業，獲碩士學位；
2002年09月至2005年07月，畢業于中南大學湘雅醫學院腫瘤研究所病理學與病理生理學專業，獲得醫學博士學位。
工作經歷
1999年08月至2002年09月于湖南省化工研究院生測所，任助理研究員。
2005年08月至2007年03月于浙江省溫州醫學院衛生部重點實驗室，從事腫瘤發病機制研究。
2007年03月至2010年06月于紐約Lindsley F. Kimball Research Institute (LFKRI)從事腫瘤分子病理機制的博士后研究工作。
2010年09月至今于湖南大學生物學院從事分子醫學相關的教學和科研工作。
研究領域
葉茂教授主要從事腫瘤生物學、抗腫瘤分子靶向治療、化學生物學等方向的研究工作。研究具體內容以惡性腫瘤細胞增殖、分化、轉移、凋亡等生物學行為為切入點，通過分子生物學、基因組學和蛋白質組學的方法和手段，探討惡性腫瘤發生、發展的分子病理學機制，尋找惡性腫瘤的早期診斷、治療或預后有指導意義的分子標志物和分子靶標，并借助生物分析和功能納米材料的方法和手段，開展惡性腫瘤分子成像、分子診斷和分子靶向治療。
科研項目
葉茂教授主持和參與了多項科研項目，包括國家自然科學基金、湖南省省自然科學基金、長沙市科技計劃等。作為co-PI主持美國Rose M.Badgeley Residuary Charitable基金一項。具體項目包括：
- 湖南省重點研發計劃（2018SK2128), 項目負責人
- 國家自然科學基金面上項目（81672760），項目負責人
- 國家科技部973項目(2013CB932702) ，子項目負責人
- 國家自然科學基金面上項目 (81272220)， 項目負責人
- 國家自然科學基金面上項目（81171950，項目負責人
- 湖南省省自然科學基金（12JJ6077）， 項目負責人
- 湖南大學交叉學科研究項目, 項目負責人
學術成果
發表文章
Hui Li, Juan Liu, Wenjie Cao, Xiaojuan Xiao, Long Liang, Feng Liu-Smith, Weiwei Wang, Hong Liu, Peng Zhou, Ruoyuan Ouyang, Zhijun Yuan, Jing Liu*, Mao Ye*, Bin Zhang*. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer. Theranostics 2019; 9(18): 5134-5148 (IF:8.063)
Wu Xiaoqiu#; Liu Honglin#; Han Dongmei#; Peng Bo; Zhang Hui; Zhang Lin; Li Jianglin; Liu Jing; Cui Cheng; Fang Senbiao; Li Min; Ye Mao*; Tan Weihong*, Elucidation and structural modeling of CD71 as a molecular target for 細胞specific aptamer binding., Journal of the American Chemical Society, 2019
Liang Long; Peng Yuanliang; Zhang Jieying; Zhang Yibin; Roy Mridul; Han Xu; Xiao Xiaojuan; Sun Shuming; Liu Hong; Nie Ling; Kuang Yijin; Zhu Zesen; Deng Jinghui; Xia Yang; Sankaran Vijay G; Hillyer Christopher D; Mohandas Narla; Ye Mao*; An Xiuli*; Liu Jing*, Deubiquitylase USP7 regulates human terminal erythroid differentiation by stabilizing GATA1., Haematologica, 2019-3-14. （IF:9.09）
Fu, Ting#; Lyu, Yifan#; Liu, Hui; Peng, Ruizi; Zhang, Xiaobing; Ye, Mao*; Tan, Weihong*. 脫氧核糖核酸Based Dynamic Reaction Networks, Trends in Biochemical Sciences, 43 (2018) 547-560.（IF:15.678）
Jin, Cheng#; Zhang, Hui#; Zou, Jianmei; Liu, Yan; Zhang, Lin; Li, Fengjie; Wang, Ruowen; Xuan, Wenjing; Ye, Mao*; Tan, Weihong*. Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy, Angewandte Chemie International Edition, 57 (2018) 8994-8997.（IF:12.102）
Deng, Tanggang#; Yan, Guobei#; Song, Xin#; Xie, Lin; Zhou, Yu; Li, Jianglin; Hu, Xiaoxiao; Li, Zhen; Hu, Jun; Zhang, Yibin; Zhang, Hui; Sun, Yang; Feng, Peifu; Wei, Dong; Hu, Bin; Liu, Jing*; Tan, Weihong*; Ye, Mao*. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and 脫氧核糖核酸 damage responses, Proceedings of the National Academy of Sciences, 115 (2018) 4678-4683.（IF:9.504）
Wu, Xiaoqiu#; Zhao, Zilong#; Bai, Huarong; Fu, Ting; Yang, Chao; Hu, Xiaoxiao; Liu, Qiaoling; Champanhac, Carole; Teng, I-Ting; Ye, Mao*; Tan, Weihong* 脫氧核糖核酸 aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition, Theranostics, 5 (2015) 985-994.（IF:8.537）
Roy, Mridul#; Liang, Long#; Xiao, Xiaojuan#; Peng, Yuanliang; Luo, Yuhao; Zhou, Weihua; Zhang, Ji; 裘姓, Lugui; Zhang, Shuaishuai; Liu, Feng; Ye, Mao*; Zhou, Wen*; Liu, Jing*. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma, Theranostics, 6 (2016) 2209.（IF:8.537）
Yi, Yi; Wang, Huijing; Wang, Xuewei; Liu, Qiaoling*; Ye, Mao*; Tan, Weihong, A Smart, Photocontrollable Drug Release Nanosystem for Multifunctional Synergistic Cancer Therapy, ACS applied materials & interfaces, 9 (2017) 5847-5854.（IF:8.097）
Peng, Lu; Wu, Cuichen Sam; You, Mingxu; Han, Da; Chen, Yan; Fu, Ting; Ye, Mao*; Tan, Weihong*, Engineering and applications of 脫氧核糖核酸grafted 均聚物 materials, Chemical science, 4 (2013) 1928-1938.（IF:9.063）
Sun, Yang#; Cao, Lanqin#; Sheng, Xunan; Chen, Jieying; Zhou, Yu; Yang, Chao; Deng, Tanggang; Ma, Hongchang; Feng, Peifu; Liu, Jing; Tan, Weihong*; Ye, Mao*. WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway, Cell 死亡 & disease, 8 (2017) e2743.（IF:5.638）
Zhang, Hui; Wang, Zhibo; Xie, Lin; Zhang, Yibin; Deng, Tanggang; Li, Jianglin; Liu, Jing; Xiong, Wei; Zhang, Lei; Zhang, Lin; Peng, Bo; He, Leye; Ye, Mao*, Hu, Xiaoxiao*; Tan, Weihong*. Molecular Recognition and In-Vitro-Targeted Inhibition of Renal 細胞 Carcinoma Using a 脫氧核糖核酸 Aptamer, Molecular Therapy-Nucleic Acids, 12 (2018) 758-768.（IF:5.66）
Hu Bin; Deng Tanggang; Ma Hongchang; Liu Yan; Feng Peifu; Wei 越南盾; Ling Neng; Li Ling; Qiu Siyuan; Zhang Lin; Peng Bo; Liu Jing; Ye Mao*, Deubiquitinase DUB3 Regulates Cell Cycle Progression via Stabilizing Cyclin A for Proliferation of Non-Small Cell Lung Cancer Cells., Cells, 8(4), 2019-3-31. （IF:4.829）
Zhou, Weihua; Zhang, Yibin; Zeng, Yayue; Peng, Minyuan; Li, Hui; Sun, Shuming; Ma, Bianying; Wang, Yanpeng; Ye, Mao*; Liu, Jing*. Screening and characterization of a Annenix A2 binding aptamer that inhibits the proliferation of myeloma cells, Biochimie, (2018).（IF:3.188）
Roy, Mridul; Liang, Long; Xiao, Xiaojuan; Feng, Peifu; Ye, Mao*; Liu, Jing*. Lycorine: A prospective natural 鉛 for anticancer drug discovery, Biomedicine & Pharmacotherapy, 107 (2018) 615-624.（IF:3.457）
Chen, Jieying#; Sheng, Xunan#; Ma, Hongchang#; Tang, Zhengshan; Yang, Chao; Cao, Lanqin; Sun, Yang; Deng, Tanggang; Feng, Peifu; Hu, Bin; Wei, 越南盾; Liu, Jing; Xiong, Wei*; Ye, Mao*. WDR79 mediates the proliferation of non‐small cell lung cancer cells by regulating the stability of UHRF1, Journal of cellular and molecular medicine, 22 (2018) 2856-2864.（IF:4.302）
Wang, Zi; Zhang, Jingxin; Zeng, Yayue; Sun, Shuming; Zhang, Ji; Zhang, Bin; Zhu, Min; Ouyang, Ruoyun; Ma, Bianyin; Ye, Mao*; An, Xiuli*; Liu, Jing*. Knockout of 4.1 B triggers malignant transformation in SV40T‐immortalized mouse embryo fibroblast cells, Molecular carcinogenesis, 56 (2017) 538-549.（IF:3.851）
Peng, Yongbo#; Zhao, Zilong#; Liu, Teng#; Xie, Guojian; Jin, Cheng; Deng, Tang gang; Sun, Yang; Li, Xiong; Hu, Xiaoxiao; Zhang, Xiaobing; Ye, Mao; Tan, Weihong*. A Multi‐Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance, ChemMedChem, 12 (2017) 250-256.（IF:3.009）
Peng, Minyuan; Li, Yanming; Zhang, Jian; Wu, Yong; Yang, Xiaoyang; Lei, Ye; Ye, Mao; Liu, Jing; Han, Xu; Kuang, Yijin; Zhao, Xielan; Chen, Fangping*. Vector-independent transmembrane transport of oligodeoxyribonucleotides involves p38 mitogen activated protein kinase phosphorylation, Scientific reports, 7 (2017) 13571.（IF:4.122）
Jin, Cheng#; Fu, Ting#; Wang, Ruowen*; Liu, Hui; Zou, Jianmei; Zhao, Zilong; Ye, Mao; Zhang, Xiaobing; Tan, Weihong*. Fluorinated molecular beacons as functional 脫氧核糖核酸 nanomolecules for cellular imaging, Chemical science, 8 (2017) 7082-7086.（IF:9.063）
Hu, Jingping; Ye, Mao; Zhou, Zhiguang*, Aptamers: novel diagnostic and therapeutic tools for 糖尿病 mellitus and metabolic diseases, Journal of Molecular Medicine, 95 (2017) 249-256.（IF:4.938）
Han, Xu; Zhang, Jieying; Peng, Yuanliang; Peng, Minyuan; Chen, Xiao; Chen, Huiyong; Song, Jianhui; Hu, Xiao; Ye, Mao; Li, Jianglin; Sankaran,Vijay G; Hillyer, Christopher D; Mohandas, Narla; An, Xiuli; Liu, Jing.Unexpected role for p19INK4d in posttranscriptional regulation of GATA1 and modulation of human terminal erythropoiesis, Blood, 129 (2017) 226-237.（IF:15.132）
Wang, Zi#; Ma, Bianyin#; Li, Hui#; Xiao, Xiaojuan#; Zhou, Weihua; Liu, Feng; Zhang, Bin; Zhu, Min; Yang, Qin; Zeng, Yayue; Sun, Yang; Sun, Shuming; Wang, Yanpeng; Zhang, Yibin; Weng, Haibo; Chen, Lixiang; Ye, Mao*; An, Xiuli*; Liu, Jing*. Protein 4.1 N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC, Oncotarget, 7 (2016) 509.
Wang, Ruowen*,#; Lu, Danqing#; Bai, Huarong#; Jin, Cheng; Yan, Guobei; Ye, Mao; Qiu, Liping; Chang, Rongshan; Cui, Cheng; Liang, Hao; Tan, Weihong*. Using modified aptamers for site specific protein–aptamer conjugations, Chemical science, 7 (2016) 2157-2161.（IF:9.063）
Sun, Yang#; Yang, Chao#; Chen, Jieying; Song, Xin; Li, Zhen; Duan, Minlan; Li, Jianglin; Hu, Xiaoxiao; Wu, Kuangpei; Yan, Guobei; Yang, Cai; Liu, Jing; Tan, Weihong*; Ye, Mao*. Overexpression of WDR 79 in non‐small cell lung cancer is linked to tumour progression, Journal of cellular and molecular medicine, 20 (2016) 698-709.（IF:4.302）
Duan, Minlan#; Long, Yuqian#; Yang, Cai; Wu, Xiaoqiu; Sun, Yang; Li, Jianglin; Hu, Xiaoxiao; Lin, Wei; Han, Dongmei; Zhao, Yifan; Liu, Jing; Ye, Mao *, Tan, Weihong *. Selection and characterization of 脫氧核糖核酸 aptamer for metastatic prostate cancer recognition and tissue imaging, Oncotarget, (2016).
Long, Yuqian#; Qin, Zhiqiang#; Duan, Minlan#; Li, Shizhu; Wu, Xiaoqiu; Lin, Wei; Li, Jianglin; Zhao, Zilong; Liu, Jing; Xiong, Dehui; Huang, Yi; Hu, Xiaoxiao; Yang, Chao; Ye, Mao*; Tan, Weihong*. Screening and identification of 脫氧核糖核酸 aptamers toward 裂體吸蟲 japonicum eggs via SELEX, Scientific reports, 6 (2016) 24986.（IF:4.122）
Li, Hui; Ouyang, Ruoyun; Wang, Zi; Zhou, Weihua; Chen, Huiyong; Jiang, Yawen; Zhang, Yibin; Liao, Mengting; Wang, Weiwei; Ye, Mao; Ding, Zhigang; Feng, Xueping*; Liu, Jing*; Zhang, Bin*. MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4, Scientific reports, 6 (2016) 39001.（IF:4.122）
Zhu, Huijie; Li, Jin; Zhang, Xiao‐Bing*; Ye, Mao; Tan, Weihong*, Nucleic acid aptamer‐mediated drug delivery for targeted cancer therapy, ChemMedChem, 10 (2015) 39-45.（IF:3.009）
Ye, Mao*,#; Tang, Yani#; Tang, Shijun#; Liu, Jing; Wu, Kuangpei; Yao, Shan; Sun, Yang; Zhou, Lei; Deng, Tanggang; Chen, Ying; Huang, Chenghan; Tan, Weihong*.STIP is a critical nuclear scaffolding protein linking USP7 to p53-Mdm2 pathway regulation, Oncotarget, 6 (2015) 34718.
Tang, Yani#; Yan, Guobei#; Song, Xin; Wu, Kuangpei; Li, Zhen; Yang, Chao; Deng, Tanggang; Sun, Yang; Hu, Xiaoxiao; Yang, Cai; Bai, Huarong; Li, Hui; Tan, Weihong; Ye, Mao*; Liu, Jing*. STIP overexpression confers oncogenic potential to human non‐small cell lung cancer cells by regulating cell cycle and apoptosis, Journal of cellular and molecular medicine, 19 (2015) 2806-2817.（IF:4.302）
Luo, Yuhao#; Roy, Mridul#; Xiao, Xiaojuan#; Sun, Shuming; Liang, Long; Chen, Huiyong; Fu, Yin; Sun, Yang; Zhu, Min; Ye, Mao; Liu, Jing*. Lycorine induces programmed necrosis in the multiple myeloma cell line ARH-77, Tumor Biology, 36 (2015) 2937-2945.
Hu, Jun#; Zhao, Zilong#; Liu, Qiaoling; Ye, Mao; Hu, Bingqiang; Wang, Jing; Tan, Weihong*. Study of the 函數 of G‐Rich Aptamers Selected for Lung Adenocarcinoma, 化學An Asian Journal, 10 (2015) 1519-1525.（IF:3.692）
Wang, Zi#; Zhang, Ji#; Ye, Mao#; Zhu, Min; Zhang, Bin; Roy, Mridul; Liu, Jing*; An, Xiuli*. Tumor suppressor role of protein 4.1 B/DAL-1, Cellular and molecular life sciences, 71 (2014) 4815-4830.（IF:6.721）
Wang, RuoWen; Zhu, Guizhi; Mei, Lei; Xie, Yan; Ma, Haibin; Ye, Mao; Qing, Feng-Ling; Tan, Weihong*, Automated modular synthesis of aptamer–drug conjugates for targeted drug delivery, Journal of the American Chemical Society, 136 (2014) 2731-2734.（IF:14.357）
Dai, Hongjuan#; Ye, Mao#; Peng, Mingyuan; Zhou, Weihua; Bai, Huarong; Xiao, Xiaojuan; Ma, Bianying; Zhou, Jiajie; Tang, Shijun; Yao, Shan; Cao, Ye; Qin, Zhiqiang; Liu, Jing*; Tan, Weihong*. Aptamer TY04 inhibits the growth of multiple myeloma cells via cell cycle arrest, Tumor Biology, 35 (2014) 7561-7568
Wang, Hui; Donovan, Michael J; Meng, Ling; Zhao, Zilong; Kim, Youngmi; Ye, Mao; Tan, Weihong*, DNAzyme‐Based Probes for Telomerase Detection in Early‐Stage Cancer Diagnosis, 化學A European Journal, 19 (2013) 4633-4639.（IF:5.16）
Roy, Mridul; Luo, Yu-Hao; Ye, Mao*; Liu, Jing*, Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors, BioMed research international, 2013 (2013).（IF:2.583）
發明專利
[1]葉茂,譚蔚泓,張慧,熊煒. 一種檢測人葡萄膜黑色素瘤細胞的核酸適體[P]. 湖南：CN108034658A,2018-05-15.（公開）
[2]譚蔚泓,孫洋,莫柳婷,趙子龍,葉茂. 一種靶向PD1#PDL1的雙特異性核酸適體及其衍生物[P]. 湖南：CN107794267A,2018-03-13.（公開）
[3]譚蔚泓,孫洋,葉茂,方曉紅,莫柳婷,趙子龍. 檢測人PDL1蛋白的核酸適體及其在制備檢測制劑中的應用[P]. 湖南：CN107794268A,2018-03-13.（公開）
[4]葉茂,譚蔚泓,胡小曉,張慧 一種檢測人腎透明細胞癌細胞的核酸適體及其在制備檢測制劑中的應用[P]. 湖南：CN106754938A,2017-05-31.（授權）
[5]葉茂,譚蔚泓,龍禹乾,段敏蘭. 一種檢測人膀胱移行細胞癌細胞的核酸適配體及其在制備檢測制劑中的應用[P]. 湖南：CN105624166A,2016-06-01.（授權）
[6]譚蔚泓,秦志強,葉茂,龍禹乾. 一種檢測日本血吸蟲卵的核酸適配體及其在制備檢測制劑中的應用[P]. 湖南：CN104962560A,2015-10-07.（授權）
[7]譚蔚泓,趙子龍,武曉秋,葉茂,白華榮. 一種檢測胰腺導管癌的核酸適配體、試劑盒及方法[P]. 湖南：CN104593372A,2015-05-06.（授權）
[8]劉靜,譚蔚泓,葉茂,宋健輝,戴紅娟. 一種核酸適配體制備治療多發性骨髓瘤的藥物或制品的用途[P]. 湖南：CN103432594A,2013-12-11.（授權）
[9]譚蔚泓,葉茂,劉靜,宋健輝,戴紅娟. 一種核酸適配體及其制備治療白血病的藥物或制品的用途[P]. 湖南：CN103409428A,2013-11-27. (授權)
獎勵榮譽
葉茂教授獲得多項獎勵和榮譽，包括：
湖南大學2019年度優秀教師
湖南省2017年自然科學二等獎 ，題目:天然小分子化合物干預腫瘤新靶點的機制研究
湖南省2010年自然科學一等獎，題目：EB病毒瘤蛋白LMP1介導的信號轉導分子機制及其功能的研究
教育部2009年度高等學?？茖W研究優秀成果（自然科學獎）二等獎，題目：EB病毒潛伏膜蛋白1致瘤分子機制的研究
溫州市2009年第十三屆自然科學優秀論文一等獎，題目：HGF通過pi3k/AKT信號轉導通路介導葡萄膜黑色素瘤轉移
參考資料 >